Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
February 13, 2024 at 04:25 pm EST
Share
Vistagen Therapeutics, Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported revenue was USD 0.4114 million compared to USD 0.1796 million a year ago. Net loss was USD 6.35 million compared to USD 9.76 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 1.42 a year ago.
For the nine months, revenue was USD 0.8667 million compared to negative revenue of USD 0.4029 million a year ago. Net loss was USD 19.84 million compared to USD 47.02 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 6.82 a year ago.
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.